Loading...
Market
Story
Summit Therapeutics' Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Stock Soars 225%
May 30, 2024, 08:01 PM
Summit Therapeutics announced that its experimental therapy, Ivonescimab, met the primary endpoint in the Harmoni-2 Phase 3 trial for non-small cell lung cancer (NSCLC) conducted in China. The drug, which targets both PD-1 and VEGF, outperformed Merck's Keytruda in progression-free survival (PFS), leading to a significant increase in Summit's stock price, which soared by 225%. The company's market cap reached $5 billion. However, it is important to note that the FDA does not recognize data from Chinese trials, which may impact future regulatory approval.
View original story
Similar markets
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%
Increase by 50% or more • 25%
Increase by 1-49% • 25%
No change or decrease by 1-49% • 25%
Decrease by 50% or more • 25%
Less than 500 million USD • 25%
500 million - 1 billion USD • 25%
1 billion - 2 billion USD • 25%
More than 2 billion USD • 25%
No new partnerships • 33%
Partner with a major pharmaceutical company • 33%
Partner with multiple smaller pharmaceutical companies • 33%
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%
Less than $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
More than $100 • 25%
Below $10 • 33%
$10 to $20 • 34%
Above $20 • 33%
